Home › Companies › INTRA-CELLULAR THERAPIES INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and INTRA-CELLULAR THERAPIES INC.’s Form 8-K, filed June 18, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 14, 2024: 4 items on INTRA-CELLULAR THERAPIES INC.’s Form 8-K, filed June 18, 2024: 2 approved · 2 passed (calculated).
Significant dissent: 1 director (41.3% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025
Explore INTRA-CELLULAR THERAPIES INC. in the interactive database Compare manager voting policies
These tallies are INTRA-CELLULAR THERAPIES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Joel S. Marcus | 54,287,176 | -- | -- | 38,126,412 | 3,812,995 | 59% | Passed (calculated) | — |
| 2. Approval of the Amended 2018 Plan, based on the following results | 85,384,880 | 2,956,962 | 4,071,746 | -- | 3,812,995 | 97% | Passed (calculated) | — |
| 3. Appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 | 88,688,988 | 3,237,807 | 4,299,788 | -- | 0 | 96% | Approved | — |
| 4. On an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement | 80,788,125 | 7,537,868 | 4,087,595 | -- | 3,812,995 | 91% | Approved | — |
Source: INTRA-CELLULAR THERAPIES INC., Form 8-K, filed with the SEC on June 18, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
363 asset managers disclosed a vote on at least one INTRA-CELLULAR THERAPIES INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
59% Majority: yes · of votes cast
Description as filed by funds: To elect one director to serve a three-year term expiring in 2027: Joel S. Marcus
INTRA-CELLULAR THERAPIES INC.’s own tally for this item (“Elect Director: Joel S. Marcus”): 54,287,176 for, 38,126,412 withheld, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 59% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 958,550 | 0 | 0 | 9,534,538 | Mixed |
| Fidelity | 10,125,019 | 0 | 0 | 61,058 | For |
| BlackRock | 0 | 0 | 0 | 4,545,940 | Withhold |
| WASATCH FUNDS TRUST | 2,135,726 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 2,049,627 | Withhold |
| T. Rowe Price | 1,258,648 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 1,099,670 | Withhold |
| Legg Mason | 1,006,717 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 990,389 | Withhold |
| JPMorgan | 892,794 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 825,243 | Withhold |
| FRANKLIN STRATEGIC SERIES | 694,609 | 0 | 0 | 0 | For |
| First Trust | 639,766 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 570,007 | Withhold |
| Lord Abbett | 463,762 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 0 | 419,947 | Withhold |
| Principal | 179,428 | 0 | 0 | 228,516 | Mixed |
| American Century | 390,414 | 0 | 0 | 0 | For |
| Equitable | 1,200 | 0 | 0 | 357,520 | Withhold |
| Brighthouse | 107,646 | 0 | 0 | 234,892 | Mixed |
| Hartford | 307,729 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 267,081 | Withhold |
| Jackson National | 62,334 | 0 | 0 | 200,406 | Mixed |
| AMG FUNDS | 253,068 | 0 | 0 | 0 | For |
| GENERAL AMERICAN INVESTORS CO INC | 244,036 | 0 | 0 | 0 | For |
Fund voting reports, all 110 managers: 22,165,607 for, 23,170,012 withheld. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| TimesSquare Capital Management, LLC | 343,606 | 0 | 0 | 0 | For |
| Altium Capital Management LP | 193,000 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 23,400 | 0 | 0 | 0 | For |
Institutional-manager reports, all 3 managers: 560,006 for.
Combines 3 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: To approve the amendment and restatement of the Company's Amended and Restated 2018 Equity Incentive Plan.
INTRA-CELLULAR THERAPIES INC.’s own tally for this item (“2. Approval of the Amended 2018 Plan, based on the following results”): 85,384,880 for, 2,956,962 against, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of INTRA-CELLULAR THERAPIES INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (3 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,493,088 | 0 | 0 | 0 | For |
| Fidelity | 10,186,077 | 0 | 0 | 0 | For |
| BlackRock | 4,545,940 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 2,135,726 | 0 | 0 | 0 | For |
| Invesco | 2,049,627 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,258,648 | 0 | 0 | 0 | For |
| Charles Schwab | 1,099,670 | 0 | 0 | 0 | For |
| Legg Mason | 1,006,717 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 990,389 | 0 | 0 | 0 | For |
| JPMorgan | 892,794 | 0 | 0 | 0 | For |
| TIAA | 825,243 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 694,609 | 0 | 0 | 0 | For |
| First Trust | 639,766 | 0 | 0 | 0 | For |
| AllianceBernstein | 570,007 | 0 | 0 | 0 | For |
| Lord Abbett | 463,762 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 419,947 | 0 | 0 | 0 | For |
| Principal | 300,618 | 107,326 | 0 | 0 | Mixed |
| American Century | 0 | 390,414 | 0 | 0 | Against |
| Equitable | 358,720 | 0 | 0 | 0 | For |
| Brighthouse | 342,538 | 0 | 0 | 0 | For |
| Hartford | 307,729 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 267,081 | 0 | 0 | 0 | For |
| Jackson National | 262,740 | 0 | 0 | 0 | For |
| AMG FUNDS | 253,068 | 0 | 0 | 0 | For |
| GENERAL AMERICAN INVESTORS CO INC | 244,036 | 0 | 0 | 0 | For |
Fund voting reports, all 109 managers: 44,552,288 for, 746,292 against, 1 withheld, 17,536 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| TimesSquare Capital Management, LLC | 343,606 | 0 | 0 | 0 | For |
| Altium Capital Management LP | 193,000 | 0 | 0 | 0 | For |
| MITCHELL CAPITAL MANAGEMENT CO | 300 | 0 | 0 | 0 | For |
Institutional-manager reports, all 3 managers: 536,906 for.
Combines 10 wordings of this item as funds reported it.
91% Approved · of votes cast
Prior year: 93.1% for (June 23, 2023 meeting) ▼ 1.6 pts
Description as filed by funds: To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in the proxy statement.
INTRA-CELLULAR THERAPIES INC.’s own tally for this item (“4. On an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement”): 80,788,125 for, 7,537,868 against — passed, per its Form 8-K filed June 18, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “On an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement was approved, based on the following votes:”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,493,088 | 0 | 0 | 0 | For |
| Fidelity | 10,186,077 | 0 | 0 | 0 | For |
| BlackRock | 4,545,940 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 2,135,726 | 0 | 0 | 0 | For |
| Invesco | 0 | 2,049,627 | 0 | 0 | Against |
| T. Rowe Price | 1,258,648 | 0 | 0 | 0 | For |
| Charles Schwab | 1,099,670 | 0 | 0 | 0 | For |
| Legg Mason | 1,006,717 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 990,389 | 0 | 0 | 0 | For |
| JPMorgan | 892,794 | 0 | 0 | 0 | For |
| TIAA | 825,243 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 694,609 | 0 | 0 | 0 | For |
| First Trust | 639,766 | 0 | 0 | 0 | For |
| AllianceBernstein | 570,007 | 0 | 0 | 0 | For |
| Lord Abbett | 463,762 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 419,947 | 0 | 0 | 0 | For |
| Principal | 407,944 | 0 | 0 | 0 | For |
| American Century | 0 | 390,414 | 0 | 0 | Against |
| Equitable | 358,720 | 0 | 0 | 0 | For |
| Brighthouse | 107,646 | 234,892 | 0 | 0 | Mixed |
| Hartford | 273,382 | 34,347 | 0 | 0 | Mixed |
| AB DISCOVERY GROWTH FUND, INC. | 267,081 | 0 | 0 | 0 | For |
| Jackson National | 0 | 262,740 | 0 | 0 | Against |
| AMG FUNDS | 253,068 | 0 | 0 | 0 | For |
| GENERAL AMERICAN INVESTORS CO INC | 244,036 | 0 | 0 | 0 | For |
Fund voting reports, all 110 managers: 42,089,931 for, 3,228,151 against, 1 withheld, 17,536 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 12,629,610 | 0 | 0 | 0 | For |
| BlackRock | 3,418,211 | 19,868 | 0 | 0 | For |
| WASATCH ADVISORS LP | 2,780,281 | 20,192 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,204,635 | 0 | 0 | 0 | For |
| State Street | 1,996,115 | 28,267 | 0 | 0 | For |
| Invesco | 0 | 2,015,113 | 0 | 0 | Against |
| Clearbridge Investments, LLC | 1,687,918 | 161 | 0 | 0 | For |
| T. Rowe Price | 1,651,072 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 1,525,991 | 0 | 0 | 0 | For |
| JPMorgan | 1,500,118 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,465,042 | 0 | 0 | 0 | For |
| Wellington | 1,423,209 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 1,372,114 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 1,291,551 | 0 | 0 | 0 | For |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,280,768 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 1,206,614 | 3,989 | 0 | 0 | For |
| Charles Schwab | 1,122,610 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 1,072,173 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 1,051,507 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 924,590 | 0 | 0 | 0 | For |
| Northern Trust | 840,634 | 5,131 | 0 | 0 | For |
| Nuveen | 829,732 | 0 | 0 | 0 | For |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 0 | 625,114 | 0 | 0 | Against |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 625,000 | 0 | 0 | 0 | For |
| LORD, ABBETT & CO. LLC | 523,218 | 0 | 0 | 0 | For |
Institutional-manager reports, all 278 managers: 54,694,995 for, 5,764,498 against, 62 not voted, 2 unknown. Showing the 25 largest; every one is in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
96% Approved · of votes cast
Description as filed by funds: To ratify of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
INTRA-CELLULAR THERAPIES INC.’s own tally for this item (“3. Appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 88,688,988 for, 3,237,807 against — passed, per its Form 8-K filed June 18, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified, based on the following results:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,493,088 | 0 | 0 | 0 | For |
| Fidelity | 10,186,077 | 0 | 0 | 0 | For |
| BlackRock | 4,545,940 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 2,135,726 | 0 | 0 | 0 | For |
| Invesco | 2,049,627 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,258,648 | 0 | 0 | 0 | For |
| Charles Schwab | 1,099,670 | 0 | 0 | 0 | For |
| Legg Mason | 1,006,717 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 990,389 | 0 | 0 | 0 | For |
| JPMorgan | 892,794 | 0 | 0 | 0 | For |
| TIAA | 825,243 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 694,609 | 0 | 0 | 0 | For |
| First Trust | 639,766 | 0 | 0 | 0 | For |
| AllianceBernstein | 570,007 | 0 | 0 | 0 | For |
| Lord Abbett | 463,762 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 419,947 | 0 | 0 | 0 | For |
| Principal | 407,944 | 0 | 0 | 0 | For |
| American Century | 390,414 | 0 | 0 | 0 | For |
| Equitable | 358,720 | 0 | 0 | 0 | For |
| Brighthouse | 342,538 | 0 | 0 | 0 | For |
| Hartford | 307,729 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 267,081 | 0 | 0 | 0 | For |
| Jackson National | 262,740 | 0 | 0 | 0 | For |
| AMG FUNDS | 253,068 | 0 | 0 | 0 | For |
| GENERAL AMERICAN INVESTORS CO INC | 244,036 | 0 | 0 | 0 | For |
Fund voting reports, all 111 managers: 45,215,652 for, 102,680 against, 1 withheld, 17,536 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| TimesSquare Capital Management, LLC | 343,606 | 0 | 0 | 0 | For |
| Altium Capital Management LP | 193,000 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 23,400 | 0 | 0 | 0 | For |
| ZIMMERMANN INVESTMENT MANAGEMENT & PLANNING LLC | 83 | 0 | 0 | 0 | For |
Institutional-manager reports, all 4 managers: 560,089 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported.
| # | Asset manager | Shares voted |
|---|---|---|
| 1 | Vanguard | 10,493,088 |
| 2 | Fidelity | 10,186,077 |
| 3 | BlackRock | 4,545,940 |
| 4 | WASATCH FUNDS TRUST | 2,135,726 |
| 5 | Invesco | 2,049,627 |
| 6 | T. Rowe Price | 1,258,648 |
| 7 | Charles Schwab | 1,099,670 |
| 8 | Legg Mason | 1,006,717 |
| 9 | Delaware/Macquarie | 990,389 |
| 10 | JPMorgan | 892,794 |
| # | Asset manager | Shares voted |
|---|---|---|
| 1 | Fidelity | 12,629,610 |
| 2 | BlackRock | 3,438,079 |
| 3 | WASATCH ADVISORS LP | 2,800,473 |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 2,204,635 |
| 5 | State Street | 2,024,382 |
| 6 | Invesco | 2,015,113 |
| 7 | Clearbridge Investments, LLC | 1,688,079 |
| 8 | T. Rowe Price | 1,651,072 |
| 9 | Deep Track Capital, LP | 1,525,991 |
| 10 | JPMorgan | 1,500,118 |
Shown as share counts, not percentages: no shares-outstanding figure has been matched to INTRA-CELLULAR THERAPIES INC. for the 2023-2024 season, so there is no denominator to divide by.
At INTRA-CELLULAR THERAPIES INC.'s shareholder meeting held June 14, 2024, in the 2023-2024 proxy season, 363 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 2,071 separate fund positions. On the most widely held item on that ballot — To approve by an advisory vote the compensation of the Company's named executive officers, as… — INTRA-CELLULAR THERAPIES INC.'s filing reports the proposal as approved, with 91% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: INTRA-CELLULAR THERAPIES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
INTRA-CELLULAR THERAPIES INC. proxy season coverage: 2023-2024 (this page) · 2024-2025.
Proxy Votes Now, “INTRA-CELLULAR THERAPIES INC. 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/intra-cellular-therapies-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.